Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Amy Hirsch"'
Autor:
Lenche Kostadinova, Carey L. Shive, Elizabeth Zebrowski, Brianna Fuller, Kelsey Rife, Amy Hirsch, Anita Compan, Anita Moreland, Yngve Falck-Ytter, Daniel L. Popkin, Donald D. Anthony
Publikováno v:
Pathogens and Immunity, Vol 3, Iss 1, Pp 149-163 (2018)
Background: During chronic hepatitis C virus (HCV) infection, Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) levels mark active liver inflammation and tissue damage, while albumin reflects synthetic liver function and nutritional
Externí odkaz:
https://doaj.org/article/a651cb373a704c528bb45bc7a62bed87
Autor:
Perica Davitkov, Apoorva Krishna Chandar, Amy Hirsch, Anita Compan, Marina G Silveira, Donald D Anthony, Suzanne Smith, Clare Gideon, Robert A Bonomo, Yngve Falck-Ytter
Publikováno v:
PLoS ONE, Vol 11, Iss 10, p e0163945 (2016)
Clinicians often face dilemmas with decisions related to formulary choices when two similar drugs are simultaneously available in the market. We studied the comparative safety, effectiveness, and treatment costs of the two first generation direct-act
Externí odkaz:
https://doaj.org/article/e0b28ffe2d2742a7978d941a3ceda23c
Autor:
Shumaker, Amy Hirsch, Bhimraj, Adarsh
Publikováno v:
In Infectious Disease Clinics of North America June 2022 36(2):349-364
Autor:
Bhimraj, Adarsh, Morgan, Rebecca L, Shumaker, Amy Hirsch, Lavergne, Valery, Baden, Lindsey, Cheng, Vincent Chi-Chung, Edwards, Kathryn M, Gandhi, Rajesh, Muller, William J, O'Horo, John C, Shoham, Shmuel, Murad, M Hassan, Mustafa, Reem A, Sultan, Shahnaz, Falck-Ytter, Yngve
Publikováno v:
Clinical Infectious Diseases; Jun2024, Vol. 78 Issue 7, pe83-e102, 20p
Autor:
Bhimraj, Adarsh, Morgan, Rebecca L, Shumaker, Amy Hirsch, Baden, Lindsey R, Cheng, Vincent Chi-Chung, Edwards, Kathryn M, Gallagher, Jason C, Gandhi, Rajesh T, Muller, William J, Nakamura, Mari M, O'Horo, John C, Shafer, Robert W, Shoham, Shmuel, Murad, M Hassan, Mustafa, Reem A, Sultan, Shahnaz, Falck-Ytter, Yngve
Publikováno v:
Clinical Infectious Diseases; Jun2024, Vol. 78 Issue 7, pe250-e349, 100p
Publikováno v:
Open Forum Infectious Diseases. 9
Background We assessed correlation between prior acceptance of COVID-19 vaccination and acceptance of monoclonal antibody (MAb) treatment for mild-to-moderate COVID-19. Methods Adult outpatients evaluated for treatment with MAb between August 31st, 2
Autor:
Jason C. Gallagher, Yngve Falck-Ytter, William J. Muller, Shmuel Shoham, Adarsh Bhimraj, John C. O’Horo, Lindsey R. Baden, Dana Swartzberg Wollins, Rajesh T. Gandhi, Amy Hirsch Shumaker, Vincent C.C. Cheng, Valery Lavergne, Kathryn M. Edwards, Rebecca L. Morgan
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Given the urgent need for treatments during the coronavirus disease 2019 pandemic, the US Food and Drug Administration issued emergency use authorizations (EUAs) for multiple therapies. In several instances, however, these EUAs were issued before suf
Autor:
Amy Hirsch Shumaker, Rajesh T. Gandhi, Kathryn M. Edwards, Vincent C.C. Cheng, Rebecca L. Morgan, Jason C. Gallagher, Lindsey R. Baden, William J. Muller, Adarsh Bhimraj, Dana Swartzberg Wollins, Yngve Falck-Ytter, John C. O’Horo, Shmuel Shoham
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Despite the challenges of the pandemic, there has been substantial progress with coronavirus disease 2019 (COVID-19) therapies. Pivotal COVID-19 trials like SOLIDARITY, RECOVERY, and ACCT-1 were rapidly conducted and data disseminated to support effe
Autor:
Adarsh Bhimraj, Rebecca L Morgan, Amy Hirsch Shumaker, Lindsey R Baden, Vincent Chi-Chung Cheng, Kathryn M Edwards, Jason C Gallagher, Rajesh T Gandhi, William J Muller, Mari M Nakamura, John C O’Horo, Robert W Shafer, Shmuel Shoham, M Hassan Murad, Reem A Mustafa, Shahnaz Sultan, Yngve Falck-Ytter
Publikováno v:
Clinical Infectious Diseases.
There are many pharmacologic therapies that are being used or considered for treatment of coronavirus disease 2019 (COVID-19), with rapidly changing efficacy and safety evidence from trials. The objective was to develop evidence-based, rapid, living
Autor:
Adarsh, Bhimraj, Rebecca L, Morgan, Amy Hirsch, Shumaker, Lindsey, Baden, Vincent Chi Chung, Cheng, Kathryn M, Edwards, Jason C, Gallagher, Rajesh T, Gandhi, William J, Muller, Mari M, Nakamura, John C, O'Horo, Robert W, Shafer, Shmuel, Shoham, M Hassan, Murad, Reem A, Mustafa, Shahnaz, Sultan, Yngve, Falck-Ytter
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
There are many pharmacologic therapies that are being used or considered for treatment of coronavirus disease 2019 (COVID-19), with rapidly changing efficacy and safety evidence from trials.Develop evidence-based, rapid, living guidelines intended to